Literature DB >> 28923553

A systematic integrated analysis of brain expression profiles reveals YAP1 and other prioritized hub genes as important upstream regulators in Alzheimer's disease.

Min Xu1, Deng-Feng Zhang2, Rongcan Luo1, Yong Wu1, Hejiang Zhou3, Li-Li Kong4, Rui Bi3, Yong-Gang Yao5.   

Abstract

INTRODUCTION: Profiling the spatial-temporal expression pattern and characterizing the regulatory networks of brain tissues are vital for understanding the pathophysiology of Alzheimer's disease (AD).
METHODS: We performed a systematic integrated analysis of expression profiles of AD-affected brain tissues (684 AD and 562 controls). A network-based convergent functional genomic approach was used to prioritize possible regulator genes during AD development, followed by functional characterization.
RESULTS: We generated a complete list of differentially expressed genes and hub genes of the transcriptomic network in AD brain and constructed a Web server (www.alzdata.org) for public access. Seventeen hub genes active at the early stages, especially YAP1, were recognized as upstream regulators of the AD network. Cellular assays proved that early alteration of YAP1 could promote AD by influencing the whole transcriptional network. DISCUSSION: Early expression disturbance of hub genes is an important feature of AD development, and interfering with this process may reverse the disease progression.
Copyright © 2017 the Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; Convergent functional genomic; Database; Differential expression; Upstream regulator

Mesh:

Substances:

Year:  2017        PMID: 28923553     DOI: 10.1016/j.jalz.2017.08.012

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  51 in total

1.  Circular HDAC9/microRNA-138/Sirtuin-1 Pathway Mediates Synaptic and Amyloid Precursor Protein Processing Deficits in Alzheimer's Disease.

Authors:  Yanjun Lu; Lu Tan; Xiong Wang
Journal:  Neurosci Bull       Date:  2019-03-18       Impact factor: 5.203

2.  An Integrative Pharmacology-Based Analysis of Refined Qingkailing Injection Against Cerebral Ischemic Stroke: A Novel Combination of Baicalin, Geniposide, Cholic Acid, and Hyodeoxycholic Acid.

Authors:  Chongyang Ma; Xueqian Wang; Tian Xu; Shuang Zhang; Shuling Liu; Changming Zhai; Zisong Wang; Jie Mu; Changxiang Li; Fafeng Cheng; Qingguo Wang
Journal:  Front Pharmacol       Date:  2020-05-08       Impact factor: 5.810

3.  Genetic association of the cytochrome c oxidase-related genes with Alzheimer's disease in Han Chinese.

Authors:  Rui Bi; Wen Zhang; Deng-Feng Zhang; Min Xu; Yu Fan; Qiu-Xiang Hu; Hong-Yan Jiang; Liwen Tan; Tao Li; Yiru Fang; Chen Zhang; Yong-Gang Yao
Journal:  Neuropsychopharmacology       Date:  2018-07-06       Impact factor: 7.853

4.  Magnolol upregulates CHRM1 to attenuate Amyloid-β-triggered neuronal injury through regulating the cAMP/PKA/CREB pathway.

Authors:  Gemin Zhu; Yuan Fang; Xiaoli Cui; Ruihua Jia; Xiaogang Kang; Rui Zhao
Journal:  J Nat Med       Date:  2021-10-27       Impact factor: 2.343

Review 5.  Harnessing endophenotypes and network medicine for Alzheimer's drug repurposing.

Authors:  Jiansong Fang; Andrew A Pieper; Ruth Nussinov; Garam Lee; Lynn Bekris; James B Leverenz; Jeffrey Cummings; Feixiong Cheng
Journal:  Med Res Rev       Date:  2020-07-13       Impact factor: 12.944

6.  Disruption of a RAC1-centred network is associated with Alzheimer's disease pathology and causes age-dependent neurodegeneration.

Authors:  Masataka Kikuchi; Michiko Sekiya; Norikazu Hara; Akinori Miyashita; Ryozo Kuwano; Takeshi Ikeuchi; Koichi M Iijima; Akihiro Nakaya
Journal:  Hum Mol Genet       Date:  2020-03-27       Impact factor: 6.150

7.  C/EBPβ is a key transcription factor for APOE and preferentially mediates ApoE4 expression in Alzheimer's disease.

Authors:  Yiyuan Xia; Zhi-Hao Wang; Jichun Zhang; Xia Liu; Shan Ping Yu; Karen X Ye; Jian-Zhi Wang; Keqiang Ye; Xiao-Chuan Wang
Journal:  Mol Psychiatry       Date:  2020-12-18       Impact factor: 15.992

8.  [Network pharmacology-based study of the therapeutic mechanism of resveratrol for Alzheimer's disease].

Authors:  Yingyan Fang; Zhenhong Su; Wenxia Si; Yuancheng Liu; Jie Li; Peng Zeng
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2021-01-30

9.  A statistical framework for cross-tissue transcriptome-wide association analysis.

Authors:  Yiming Hu; Mo Li; Qiongshi Lu; Haoyi Weng; Jiawei Wang; Seyedeh M Zekavat; Zhaolong Yu; Boyang Li; Jianlei Gu; Sydney Muchnik; Yu Shi; Brian W Kunkle; Shubhabrata Mukherjee; Pradeep Natarajan; Adam Naj; Amanda Kuzma; Yi Zhao; Paul K Crane; Hui Lu; Hongyu Zhao
Journal:  Nat Genet       Date:  2019-02-25       Impact factor: 38.330

10.  Discovery and Validation of Key Biomarkers Based on Immune Infiltrates in Alzheimer's Disease.

Authors:  Zhuohang Liu; Hang Li; Shuyi Pan
Journal:  Front Genet       Date:  2021-07-01       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.